Tumor Suppressor Genes in Lung Cancer
Lung cancer is the number-one cancer killer of both men and women in the United States, killing more than 150,000 people every year. Lung cancer consists of two broad groups: small-cell lung cancers (SCLC), which account for about 25% of bronchogenic carcinomas, and the remaining tumors, non-small-cell lung cancers (NSCLC). SCLC cells possess neuroendrocrine-like properties, whereas most NSCLC lack these functions and can be divided into three major subtypes, adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma (LC). SCLC is one of the most virulent forms of human cancer, characterized by early dissemination and aggressive clinical evolution as compared to NSCLC. The initial responsiveness of SCLC to anticancer drugs and radiation treatment contrasts with the relative resistance of NSCLC to the same types of interventions. The reasons for the differences between SCLC and NSCLC are not fully understood, and one possible explanation may be resistance to killing via programmed cell death or apoptosis.
- Single-Strand Conformation Polymorphism Mutation Analysis of the p53 Gene
- Preparation and Characterization of Doxorubicin Liposomes
- Antigen-Pulsed Dendritic Cell Approach to Melanoma
- Ovarian Cancer Gene Therapy with BRCA1An Overview
- Molecular Mechanisms of Drug Resistance in Single-Step and Multi-Step Drug-Selected Cancer Cells
- Economical Protocol for Combined Single-Strand Conformation Polymorphism and Heteroduplex Analysis on a Standard Capillary Elect
- Molecular Analysis of Genetic Instability Caused by Chronic Inflammation
- Induction of Tumor Cell Apoptosis by TRAIL Gene Therapy
- Assays for Raf-1 Kinase Phosphorylation and Activity in Human Small Cell Lung Cancer Cells
- The Androgen Receptor CAG Repeat and Prostate Cancer Risk